JP2006501269A - 血管新生を処置するためのｐｄｅｉｖインヒビターの使用 - Google Patents
血管新生を処置するためのｐｄｅｉｖインヒビターの使用 Download PDFInfo
- Publication number
- JP2006501269A JP2006501269A JP2004536198A JP2004536198A JP2006501269A JP 2006501269 A JP2006501269 A JP 2006501269A JP 2004536198 A JP2004536198 A JP 2004536198A JP 2004536198 A JP2004536198 A JP 2004536198A JP 2006501269 A JP2006501269 A JP 2006501269A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- pde
- angiogenesis
- present
- edema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 23
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 17
- 206010030113 Oedema Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 208000022873 Ocular disease Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 150000003431 steroids Chemical class 0.000 description 12
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 206010055665 Corneal neovascularisation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000964 angiostatic effect Effects 0.000 description 4
- 201000000159 corneal neovascularization Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 230000002497 edematous effect Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- -1 4-ethoxycarbonylaminobenzyl Chemical group 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000002634 heparin fragment Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- ALDSXDRDRWDASQ-UHFFFAOYSA-N 2-(3-benzoylphenyl)acetic acid Chemical class OC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ALDSXDRDRWDASQ-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- OKFWVUAEZATIDY-UHFFFAOYSA-N 2-propan-2-yl-7h-purine;hydrochloride Chemical compound Cl.N1C(C(C)C)=NC=C2N=CN=C21 OKFWVUAEZATIDY-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- QAXDVKBGZRMSHF-UHFFFAOYSA-N 6-acetyl-5-hydroxy-4-methoxy-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(OC)=C(O)C2=C1CCN2C(C)=O QAXDVKBGZRMSHF-UHFFFAOYSA-N 0.000 description 1
- TYNSUEXNGLNQSS-UHFFFAOYSA-N 6-carbamoyl-5-hydroxy-4-methoxy-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(OC)=C(O)C2=C1CCN2C(N)=O TYNSUEXNGLNQSS-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000004232 retinal microvasculature Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41100102P | 2002-09-16 | 2002-09-16 | |
| PCT/US2003/028675 WO2004024085A2 (en) | 2002-09-16 | 2003-09-11 | Use of pde iv inhibitors to treat angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501269A true JP2006501269A (ja) | 2006-01-12 |
| JP2006501269A5 JP2006501269A5 (https=) | 2006-07-06 |
Family
ID=31994234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536198A Pending JP2006501269A (ja) | 2002-09-16 | 2003-09-11 | 血管新生を処置するためのｐｄｅｉｖインヒビターの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20040053939A1 (https=) |
| EP (1) | EP1539174A4 (https=) |
| JP (1) | JP2006501269A (https=) |
| KR (1) | KR20050043923A (https=) |
| CN (1) | CN1681510A (https=) |
| AR (1) | AR041263A1 (https=) |
| AU (1) | AU2003267161A1 (https=) |
| BR (1) | BR0314364A (https=) |
| CA (1) | CA2497192A1 (https=) |
| MX (1) | MXPA05002146A (https=) |
| PL (1) | PL374659A1 (https=) |
| TW (1) | TW200412972A (https=) |
| WO (1) | WO2004024085A2 (https=) |
| ZA (1) | ZA200501477B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2851247B1 (fr) * | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
| SI1755616T1 (sl) * | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| WO2007056457A2 (en) | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| EP2117524B8 (en) * | 2007-01-29 | 2019-09-25 | National Research Council of Canada | Use of catecholamines and related compounds as anti-angiogenic agents |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10502630A (ja) * | 1994-07-11 | 1998-03-10 | 藤沢薬品工業株式会社 | 複素二環式誘導体 |
| WO2000018768A1 (en) * | 1998-09-29 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel salts of pyridopyrazine compound and crystals thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570579B1 (fr) * | 1984-09-26 | 1987-01-09 | Salomon Sa | Dispositif de fermeture et de serrage d'une chaussure de ski a ouverture arriere |
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| AU6823098A (en) * | 1997-02-28 | 1998-09-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| US5866872A (en) * | 1997-07-25 | 1999-02-02 | Hypertherm, Inc. | Plasma arc torch position control |
| DE19812515A1 (de) * | 1998-03-21 | 1999-09-23 | M & F Entw & Patentverwertungs | Lamellenschleifwerkzeug |
| US6740664B2 (en) * | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
| US6326888B1 (en) * | 1998-12-17 | 2001-12-04 | Ching-Yung Wang | Auxiliary safety warning light system for a vehicle |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
-
2003
- 2003-09-11 KR KR1020057003469A patent/KR20050043923A/ko not_active Withdrawn
- 2003-09-11 MX MXPA05002146A patent/MXPA05002146A/es unknown
- 2003-09-11 ZA ZA200501477A patent/ZA200501477B/en unknown
- 2003-09-11 AU AU2003267161A patent/AU2003267161A1/en not_active Abandoned
- 2003-09-11 PL PL03374659A patent/PL374659A1/xx not_active Application Discontinuation
- 2003-09-11 EP EP03749635A patent/EP1539174A4/en not_active Ceased
- 2003-09-11 US US10/660,152 patent/US20040053939A1/en not_active Abandoned
- 2003-09-11 CN CNA038215454A patent/CN1681510A/zh active Pending
- 2003-09-11 US US10/527,599 patent/US20060014782A1/en not_active Abandoned
- 2003-09-11 WO PCT/US2003/028675 patent/WO2004024085A2/en not_active Ceased
- 2003-09-11 BR BR0314364-3A patent/BR0314364A/pt not_active IP Right Cessation
- 2003-09-11 CA CA002497192A patent/CA2497192A1/en not_active Abandoned
- 2003-09-11 JP JP2004536198A patent/JP2006501269A/ja active Pending
- 2003-09-15 AR ARP030103340A patent/AR041263A1/es not_active Application Discontinuation
- 2003-09-15 TW TW092125341A patent/TW200412972A/zh unknown
-
2005
- 2005-08-16 US US11/204,938 patent/US20050277648A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10502630A (ja) * | 1994-07-11 | 1998-03-10 | 藤沢薬品工業株式会社 | 複素二環式誘導体 |
| WO2000018768A1 (en) * | 1998-09-29 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel salts of pyridopyrazine compound and crystals thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003267161A1 (en) | 2004-04-30 |
| US20060014782A1 (en) | 2006-01-19 |
| MXPA05002146A (es) | 2005-05-23 |
| PL374659A1 (en) | 2005-10-31 |
| EP1539174A4 (en) | 2006-10-25 |
| WO2004024085A3 (en) | 2004-04-29 |
| KR20050043923A (ko) | 2005-05-11 |
| CA2497192A1 (en) | 2004-03-25 |
| TW200412972A (en) | 2004-08-01 |
| AR041263A1 (es) | 2005-05-11 |
| US20050277648A1 (en) | 2005-12-15 |
| BR0314364A (pt) | 2005-07-19 |
| ZA200501477B (en) | 2006-10-25 |
| WO2004024085A2 (en) | 2004-03-25 |
| US20040053939A1 (en) | 2004-03-18 |
| CN1681510A (zh) | 2005-10-12 |
| EP1539174A2 (en) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| JP2006512318A5 (https=) | ||
| US20040092558A1 (en) | Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases | |
| JP2014198730A (ja) | 眼の疾患、ならびに増殖および脈管形成応答に関連する疾患の処置に関する５，６，７−トリヒドロキシヘプタン酸およびアナログ | |
| JP2006501269A (ja) | 血管新生を処置するためのｐｄｅｉｖインヒビターの使用 | |
| JP2007056041A (ja) | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 | |
| Guzun et al. | Current strategy of treatment for neovascular glaucoma secondary to retinal ischemic lesions | |
| US20040259765A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2007500250A5 (https=) | ||
| Rolim-de-Moura | Glaucoma Associated with Acquired Conditions | |
| Garg et al. | Ophthalmologic Disease in Systemic Lupus Erythematosus and Antiphospholipid Syndrome | |
| CN117479932A (zh) | 用于退行性视网膜疾病的吡唑啉酮化合物 | |
| Farzad et al. | Visual impairment in the elderly | |
| Ionides et al. | Vitreous, Choroid, and Retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090826 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100630 |